🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Keri Toner

George Washington University Hospital

ORCID: 0000-0002-9324-7314

Also affiliated with Children's National, George Washington University, University of Washington, Center for Cancer and Blood Disorders

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma”.

Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma

Blood Advances(2021)10.1182/bloodadvances.2021005343
N/A
0.641DataRank · unranked
19 citations

Madeline Terpilowski, Mimi Mai, Keri Toner, Melanie Grant, Maja Stanojević +12 more

Tumor-specific immune responses and biomarkers in pediatric patients with high-risk Hodgkin lymphoma

Blood Advances(2025)10.1182/bloodadvances.2025016797
N/A
0.208DataRank · unranked
3 citations

Lindsay A. Renfro, Hema Dave, G. Pezzella, Qinglin Pei, Lisa Giulino‐Roth +6 more

EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target

Blood(2021)10.1182/blood.2020005466
N/A
0DataRank · unranked
47 citations

Catherine M. Bollard, Keri Toner

Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia

Molecular Therapy — Methods & Clinical Development(2021)10.1016/j.omtm.2021.09.008
N/A
0DataRank · unranked
18 citations

Stacey Van Pelt, Keri Toner, Preethi B. Balakrishnan, Hema Dave, Catherine M. Bollard +2 more

CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?

Seminars in Hematology(2023)10.1053/j.seminhematol.2023.11.007
N/A
0DataRank · unranked
12 citations

Catherine M. Bollard, Keri Toner, Hannah Kinoshita

Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era

Blood Advances(2025)10.1182/bloodadvances.2024014745
N/A
0DataRank · unranked
7 citations

Victor Ritter, Jennifer E. Agrusa, Kala Y. Kamdar, Julie Rivers, Rebecca Gardner +21 more